en

For investors

Nightingale as an investment ↘
Financial information ↘
Share and shareholders ↘
Governance ↘
Investor relations ↘
Releases ↘
Reports and recordings ↘

Board of Directors

The Board of Directors has general responsibility for Nightingale Health’s governance and the appropriate organization of operations. The Board of Directors has approved rules of procedure that define the matters within the Board of Directors’ responsibility. The Board of Directors affirms the principles of Nightingale Health’s strategy, organization, accounting, and controlling the management of assets, and appoints the CEO. The CEO is responsible for carrying out the strategy of Nightingale Health and for day-to-day administration based on the instructions and orders issued by the Board of Directors.

The company’s Board of Directors consists of a minimum of 3 and a maximum of 10 ordinary members. The term of office of the members of the Board of Directors expires at the end of the first Annual General Meeting of Shareholders following their election. The Board of Directors elects a Chairman from among its members for the duration of its term of office.

Nightingale Health’s Board of Directors

Leena Niemistö

  • Chair of the board since 2022
  • Born 1963
  • Finnish citizen
  • MD, PhD
  • Main work experience: Dextra Oy, Chief Executive Officer, 2003–2016; Pihlajalinna Oyj, Deputy CEO and Executive Vice President of Private Clinics and Specialised Care, 2013–2016; Orton Foundation, Specialist in Physical and Rehabilitation Medicine, 1997–2004
  • Simultaneous positions of trust: Nexstim Oyj, Chair of the board; Opera and Ballet Support Foundation, Chair of the board; Pihlajalinna Oyj, Vice Chair of the board; Yliopiston Apteekki Oy, Board member; Raisio Oyj, Board member; Suomen Messut Oyj, Board member; Digital Workforce Services Oy, Board member; Vapaus Bikes Finland Oy, Chair of the board; LymphaTouch Oy, Chair of the board; DBC Global Oy, Chair of the board
  • Holdings in the company: 403,340 Series A shares, 231,770 Series A options, entitling to same amount of shares in the company. In addition, stock options equalling to 1 per cent of the company’s shares on fully diluted basis shall be vested based on reaching target valuation, i.e. the company’s pre-money valuation in connection to a financing round, trade sale or IPO exceeding EUR 500 million. Additionally, the right to stock options equalling to 1 per cent of the company’s shares on fully diluted basis shall be vested based on reaching target valuation, i.e. the company’s pre-money valuation in connection to a financing round, trade sale or IPO exceeding EUR 1 billion. In addition, Kaikarhenni Oy, a company controlled by Leena Niemistö, holds 74,074 Series B shares.
  • Independent from the company and from major shareholders

Antti Kangas

  • Board member since 2013
  • Nightingale's CTO and Management Team member
  • Born 1984
  • Finnish citizen
  • M.Sc. (Tech)
  • Main work experience: University of Oulu, Researcher, 2008–2015; Helsinki University of Technology, Research Assistant, 2006–2008; Innofactor Oyj, Software Developer, 2004–2006; Freelance Software Developer, Graphics Designer and Information Visualisation Consultant, 1998–2003
  • Holdings in the company: 5,340,342 Series A shares, 17,458 Series B shares, 0 options
  • Not independent from the company or from major shareholders

Olli Karhi

  • Board member since 2015
  • Born 1963
  • Finnish citizen
  • Lic. Med. MD
  • Main work experience: Health City Finland, Chief Executive Officer, 2020–; KI-Technology Oy, Chief Executive Officer, 2014–; Cordis Oy, Chief Executive Officer, 2010–
  • Simultaneous positions of trust: Labquality Oy, Chairman of the board; Skulle Implants Oy, Board member; Olfactomics Oy, Board member; Kuntokeskus Liikku Oy, Board member; KI-Technology Oy, Board member; Mectalent Medical Service Oy, Chairman of the board; Mectalent Oy, Chairman of the board; Cor Group Oy, Board member; Health City Finland, Board member
  • Holdings in the company: 0 shares, 0 options
  • Independent from the company but not independent from major shareholders

Ilkka Laurila

  • Board member since 2023
  • Born 1977
  • Finnish citizen
  • MSc (Forestry), MSc (Econ)
  • Main work experience: Group CFO, 2024-, Taaleri Oyj; Chief Financial Officer, 2023–2024, Plugit Finland Oy; Management consultant, 2022-2023; Chief Financial officer and Member of Executive Team, 2015-2022, Terveystalo; Head of Treasury and Finance and Head of Procurement, Rahoituksen neuvontapalvelut Inspira Oy; Associate Director, Ernst & Young Oy
  • Simultaneous positions of trust: Adamant Health Oy, Chair of the Board; Temepa Infra Oy, Member of the Board
  • Holdings in the company: 8,000 shares, 600,000 Series B options with the right to subscribe in case defined market value is reached
  • Independent of the company and its major shareholders

Timo Soininen

  • Board member since 2020
  • Born 1965
  • Finnish citizen
  • M.Sc. (Econ)
  • Main work experience: Small Giant Games Oy, Chief Executive Officer and Co-founder, 2014–2020; Sulake Corporation Oy, Chief Executive Officer, 2001–2010; StepStone Oy, Marketing Director, 2000–2001; United Biscuits Nordic – Fazer Keksit Oy, Marketing Manager, 1995–2000
  • Simultaneous positions of trust: Small Giant Games Oy, Chairman of the Board; Spinnova Oyj, Chairman of the Board; Critical Force Entertainment, Advisor; Villagecape Ventures Oy, Member of the board
  • Holdings in the company: 447,888 Series A shares, 123,000 Series B shares, 1,362,025 Series A options, entitling to same amount of shares in the company. In addition, stock options equalling to 1 per cent of the company’s shares on fully diluted basis shall be vested based on reaching target valuation, i.e. the company’s pre-money valuation in connection to a financing round, trade sale or IPO exceeding EUR 500 million. Additionally, the right to stock options equalling to 1 per cent of the company’s shares on fully diluted basis shall be vested based on reaching target valuation, i.e. the company’s pre-money valuation in connection to a financing round, trade sale or IPO exceeding EUR 1 billion. In addition, Villagecape Ventures Oy, Timo Soininen's closely associated company over which Timo Soininen does not have control, holds 201,670 Series A shares and 59,259 Series B shares.
  • Independent from the company and from major shareholders

Teemu Suna

  • Board member since 2016
  • Nightingale’s CEO and Management Team member
  • Born 1982
  • Finnish citizen
  • M.Sc. (Tech)
  • Main work experience: Fujitsu Services Oy, Chief Technology Officer, 2011–2014; Fujitsu Services Oy, Principal Solutions Architect, 2007–2011; Ramse Consulting Oy, ICT Consultant, 2006–2007; Aalto yliopisto, ICT and Advanced Data Analysis Researcher, 2005-2006; Brainshake Oy, Director and Co-Founder, 2002-2005
  • Holdings in the company: 2,637,964 Series A shares, 31,237 Series B shares, 3,000,000 Series B options, entitling to same amount of shares in the company, with the right to subscribe in case defined market valuation is reached
  • Not independent from the company or from major shareholders

Scientific advisory board

In addition to the governing bodies of Nightingale Health, the company has established a Scientific Advisory Board. The Scientific Advisory Board is not a decision-making body but acts in a supporting role to advance Nightingale Health's strategy to translate novel scientific findings from flagship biobanks and research cohorts to preventive health applications available for individuals globally. Nightingale Health's Scientific Director acts as the Chairman of the Scientific Advisory Board.

Members of the scientific advisory board are:

Prof. John Danesh
University of Cambridge, UK

Prof José Ordovás
Tufts University, USA

Prof. Eline Slagboom
Leiden University, Netherlands

Prof. George Davey Smith
University of Bristol, UK